ClinicalTrials.gg
RecruitingNCT06711666Neuro-MomsUpdated Jul 30, 2026

Prenatal Maternal Mental Health and Neurodevelopment in Congenital Heart Disease

An observational study in Congenital Heart Disease, Cyanotic Congenital Heart Disease and d-Transposition of the Great Arteries, sponsored by Institut National de la Santé Et de la Recherche Médicale, France. Recruiting at 5 sites in France. Open to participants aged Up to 50 Years. Per ClinicalTrials.gov, last updated 2026-07-30.

Primary conditionHypoplastic Left Heart SyndromeRegistry: Heart Defects, CongenitalReclassifiedWhy we changed it
Registry
Heart Defects, Congenital — the first condition term the registry derived for this study.
ClinicalTrials.gg
Hypoplastic Left Heart Syndrome
Why
  1. The study's listed conditions name Hypoplastic Left Heart Syndrome, a narrower term within Heart Defects, Congenital.
Confidence
High: the new condition is named in the study's own listed conditions. Of 351 hand-checked studies reclassified this way, 68% were exactly right and 84% in the right disease family; the registry's first term was right for 5% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by Institut National de la Santé Et de la Recherche Médicale, France · Observational

How we know

From the registry’s dates

  • Started Jun 2025; still recruiting 1 year 4 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
174
Ages
Up to 50 Years
Sex
All
01

Study summary

Congenital heart disease (CHD) is the leading cause of congenital malformations, representing 1% of live births. Progress in surgical care have led to the dramatic increase in the population of children and adults living with heart disease. As survival is no longer a concern, long-term outcomes have become the major public health issue. Prenatal diagnosis of CHD requiring open-heart surgery can be a traumatic event for expecting mothers and fathers. In the general population, maternal mental health distress is associated with fetal disturbances in the hypothalamic-adrenal-pituitary system axis, restricted intrauterine growth and adverse outcomes in the offspring. It is unknown whether prenatal maternal psychological distress have an impact on neurodevelopmental outcomes in CHD. Our national study seeks to (1) characterize the impact of prenatal maternal psychological distress on neurodevelopmental outcomes at age 1 for children with CHD who undergo neonatal open-heart surgery; (2) investigate the sociodemographic and medical determinants associated with prenatal maternal mental health of women carrying a foetus diagnosed with complex CHD; (3) explore the mediating role of prenatal risk factors (i.e., sociodemographic, medical and maternal coping mechanisms) in the association of prenatal maternal mental health (i.e., distress, anxiety and depression) and neurodevelopment in children with CHD; and (4) explore the impact of paternal or the co-parent's mental health impact on neurodevelopmental outcomes at age 1 in children with CHD. This study is a non-interventional, prospective, and longitudinal study of prenatal maternal mental health and subsequent child's neurodevelopmental and behavioural outcomes. It includes a follow-up period from the 3rd trimester of pregnancy until the child's first year of life. It will include children with a prenatally diagnosed heart defect requiring open-heart surgery within the first weeks of life. Understanding and preventing the neurodevelopmental sequelae of heart disease diagnosed in-utero is a public health priority.

Read the detailed description

This study is a non-interventional, prospective, and longitudinal study of prenatal maternal mental health and subsequent child's neurodevelopmental and behavioural outcomes in congenital heart disease. It includes a follow-up period from the 3rd trimester of pregnancy until the child's first year of life (between 12 and 18 months). It will include children with a prenatally diagnosed critical heart defect (i.e., cyanotic types of CHD with the potential to cause rapid hypoxemia after birth) requiring neonatal open-heart surgery (within the first weeks of life).

Expecting mothers who agree to participate will undergo comprehensive psychological evaluations conducted by a licensed mental health professional with defined expertise in perinatal mental health. Fathers or co-parent of the child with foetal CHD will also participate in self-reports during the prenatal period. A total of three time points of psychological assessment will be done: Time 1, during the prenatal period, after 28 weeks of gestation); Time 2, an interim self-report assessment using only questionnaires before post-surgery hospital discharge for the baby (after intensive care transfer to hospitalization); and Time 3, 1 year after the birth of their child. Maternal assessments will include standardized self-report measures of stress, anxiety, depression and other psychological symptoms as well as a clinical interview for Time 1 and 2. Co-parent assessment at Time 1 will include self-reports of overall mental health, anxiety and coping skills.

Infant neurodevelopmental and behavioural assessments will be conducted at year 1 (between 12-18 months for the child) during a joint visit of the dyad mother-child. All assessments will be standardized and have French norms and instructions for parents and the child. These assessments will evaluate areas such as cognition, emerging language, and motor skills (gross and fine motor abilities). Socio-behavioural outcomes will also be evaluated at this time. All infant developmental assessments will be administered by paediatric neuropsychologists.

02

Conditions studied

  • Congenital Heart Disease
  • Cyanotic Congenital Heart Disease
  • d-Transposition of the Great Arteries
  • Hypoplastic Left Heart Syndrome

Browse trials for

Keywords

  • psychological stress
  • Maternal prenatal mental health
  • Neurodevelopment
  • Cyanotic congenital heart disease
  • Prenatal diagnosis
03

In context

Hypoplastic Left Heart Syndrome Reclassified

67 studies on the registry are indexed under Hypoplastic Left Heart Syndrome; 12 are open to participants now.

This study's planned enrollment of 174 is above the median of 100 across 23 observational studies indexed under Hypoplastic Left Heart Syndrome.

Browse Hypoplastic Left Heart Syndrome studies →

Lead sponsor

Institut National de la Santé Et de la Recherche Médicale, France is the lead sponsor of 378 studies on the registry; 81 are open to participants now.

Compared within Hypoplastic Left Heart Syndrome, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Heart Defects, Congenital. The counts are of registry records indexed under each term, refreshed daily. How we classify →

04

Who can participate

Ages eligible
Up to 50 Years
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Expecting women diagnosed with a foetal complex congenital heart disease. Fathers or co-parent of prenatally diagnosed children with CHD Children with complex congenital heart disease who require neonatal open-heart surgery.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion Criteria for the mother of a child diagnosed with CHD:

  1. Age at least 18 years old
  2. Expecting women
  3. Having received a diagnosis of foetal critical cyanotic CHD (i.e., CHD physiology that can compromise blood oxygenation after birth). This type of CHDs corresponds to the highest level of neurological risk as reported by the American Heart Association guidelines(1).
  4. Pregnancy of at least 28 weeks of gestation (third trimester) and up to the 38 weeks of gestation at the time of enrolment and prenatal visit for the study.
  5. Medical maternal and paediatric cardiology follow-up in one of the investigating hospitals (Montpellier, Necker Children's Hospital in Paris and Bordeaux).
  6. A delay of a minimum of 4 weeks between the initial diagnosis of foetal congenital heart disease.
  7. Social security affiliation in France.

Inclusion criteria

Inclusion criteria for the father or co-parent:

  1. Co-parent of an expecting woman participating in the study
  2. Age at least 18 years old
  3. Social security affiliation in France.

Inclusion criteria for the child diagnosed with congenital heart disease:

  1. Child with a prenatal diagnosis of isolated complex congenital heart disease, born to a mother already participating in the study
  2. Written consent from both parents
  3. Social security affiliation in France.

Non-inclusion Criteria for mothers:

  1. Patient refusal to participate
  2. Participants (i.e., expecting women) who express a wish for medical termination of pregnancy
  3. Diagnosis of a complex CHD associated with another foetal comorbidity with a clinically recognized impact on neurodevelopment (e.g., genetic syndromes such as trisomies, poly-malformation syndromes).
  4. Participants who are not able to understand the instructions and/or complete the self-reports
  5. Expecting women who currently have a major psychiatric condition (e.g., untreated major depression, severe anxiety disorders, psychotic disorders) with or without treatment, at the time of the cardiology consultation or at the time of the first psychological evaluation. Patients who will be excluded due to these conditions will be referred for perinatal psychiatric consultation.
  6. Persons under legal or judicial guardianship.

Non-inclusion Criteria for fathers or co-parents:

  1. Patient refusal to participate
  2. Participants with a severe psychiatric disorder (severe depression, psychotic disorders) with or without treatment
  3. Persons under legal or judicial guardianship.

Exclusion Criteria for the mother of a child diagnosed with CHD:

1. The child has not undergone surgery within 60 days of birth.

Exclusion criteria

Exclusion Criteria for children with CHD:

1. Genetic anomalies, brain malformations that may render difficult the neurodevelopmental assessment.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
174 participants (estimated)
Patient registry
No
06

What researchers measure

Primary outcomes

  1. Global Mental Health Self-questionnaire, The Symptom Checklist-90-Revised SCL-90 R (min score 20 - max score 80)

    Mental Health Self-Report, Higher scores indicate worse outcomes

    Time frame: Time 1 Prenatal Visit and Time 3 1-year old Visit

  2. Bayley Scales of Infant and Toddler Development (BAYLEY-4) (min score 50- max score 150)

    Standardized Neurodevelopmental Assessment, Higher scores better outcome, Mean 100; SD 15

    Time frame: Time 3 1-year old Visit

Secondary outcomes

  1. State-Trait Anxiety Inventory (STAI-Y) (min score 20 - max score 80)

    Anxiety self-report, Higher scores worse outcomes

    Time frame: Time 1 Prenatal Visit, Time 2 immediately after the neonatal open-heart surgery during postoperative hospitalization, Postoperative Visit and Time 3 1-year old Visit

  2. Coping Inventory for Stressful Situations (CISS), (min score 20 - max score 80)

    Coping self-report, Higher scores better outcomes

    Time frame: Time 1 Prenatal Visit and Time 3 1-year old Visit

  3. Post-partum depression Edinburgh Scale (EPDS) (min score 0 - max score 30)

    Post-partum depression self-report, Higher scores worse outcomes

    Time frame: Time 2 immediately after the neonatal open-heart surgery during postoperative hospitalization, Postoperative Visit

  4. Post-Traumatic Stress Scale (PCL-5), (min score 0 - max score 80)

    Self-report scale on PTSD symptoms, Higher scores worse outcomes

    Time frame: Time 3 1-year old Visit

  5. Ages and Stages Parent Report, 3rd Edition (min score 0 - max score 60)

    Developmental questionnaire for parents, Higher scores worse outcomes

    Time frame: Time 3 1-year old Visit

07

Study locations

5 of 5 sites recruiting
08

References and documents

Publications

  • Deninotti J, Derridj N, Martins S, Laux D, Stos B, Levy M, Desnous B, Guillaumont S, Amedro P, Chabaneix J, Pfister M, Marguin G, Desmure G, Vincenti M, Bonnet D, Calderon J. Prenatal maternal mental health and neurodevelopment in congenital heart disease in France: the neuro-moms CHD multicentre prospective study protocol. BMJ Open. 2025 Dec 23;15(12):e104889. doi: 10.1136/bmjopen-2025-104889. PubMed 41436266 ↗
09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Jun 2025 (actual). Primary completion is estimated for Oct 2028, 40 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 20, 2024
First posted
Dec 2, 2024
StartActual
Jun 27, 2025
Primary completionEst.
Oct 2028
CompletionEst.
Feb 2029
Last update
Jul 30, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 30, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06711666
Responsible party
Sponsor
First posted
Dec 2, 2024
Start date
Jun 27, 2025
Primary completion
Oct 2028 (estimated)
Completion
Feb 2029 (estimated)
Last update
Jul 30, 2026

Study contacts

Johanna Calderon, PhD
Contact
johanna.calderon@inserm.fr
330603830737

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion